Targeting microRNA miR-409-3P to treat prostate cancer

Patent metadata

Field	Value
Publication number	US-9745578-B2
Application number	US-201514863828-A
Country	US
Kind code	B2
Filing date	Sep 24, 2015
Priority date	Nov 30, 2011
Publication date	Aug 29, 2017
Grant date	Aug 29, 2017

Abstract

The present invention describes methods of treating cancer, cancer metastasis, and drug resistant cancers using miRNA inhibitors; for example, inhibitors of miR-409-5p, miR-409-3p, miR-154*. Also described are methods of using the miRNA as biomarkers; for example, to predict responsiveness to a cancer drug, to detect a disease state of cancer.

First claim

What is claimed is:

1. A method, comprising:
providing a miRNA inhibitor; and
administering the miRNA inhibitor to a subject in need of treatment for cancer, in need of treatment for cancer metastasis, or in need of lowering or treatment for cancer drug resistance to treat cancer, to treat cancer metastasis, or to lower or treat cancer drug resistance, wherein the cancer is prostate cancer metastasis to the bone or metastatic prostate cancer, and
wherein the miRNA inhibitor is an shRNA or siRNA capable of inhibiting miR-409-3p and/or mature miR-409-3p.

2. The method of claim 1 , further comprising administering to the subject radiation treatment or chemotherapy treatment.

3. The method of claim 1 , wherein the miRNA inhibitor is a shRNA directed against a mature miRNA, wherein the miRNA is miR-409-3p.

4. The method of claim 1 , wherein the miRNA inhibitor is a siRNA directed against a mature miRNA, wherein the miRNA is miR-409-3p.

5. The method of claim 1 , wherein the miRNA inhibitor is encoded by a polynucleotide as disclosed by SEQ ID NO:23 and administering comprises administering the polynucleotide.

6. The method of claim 1 , wherein the miRNA inhibitor is a shRNA or a siRNA capable of interfering the expression of SEQ ID NO:9.

7. The method of claim 1 , wherein the cancer is prostate cancer metastasis to the bone.

8. The method of claim 1 , wherein the cancer is metastatic prostate cancer.

Assignees

• Cedars Sinai Medical Center

Inventors

• Chung Leland W K
• Josson Sajni
• Gururajan Murali
• Jain Anjali

Classifications

• C12N2310/14

  interfering nucleic acids [NA] · CPC title

• C12N2310/3233

  Morpholino-type ring · CPC title

• C12N15/113 Primary

  Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title

• C12N2310/113

  targeting other non-coding nucleic acids, e.g. antagomirs · CPC title

• C12N2310/531

  Stem-loop; Hairpin · CPC title